| Systematic (IUPAC) name | |
|---|---|
| 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione | |
| Identifiers | |
| CAS number | 17902-23-7 |
| ATC code | L01BC03 |
| PubChem | 5386 |
| Chemical data | |
| Formula | C8H9FN2O3 |
| Mol. mass | 200.16 g/mol |
| SMILES | eMolecules & PubChem |
| Synonyms | 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
℞ Prescription only |
| Routes | Oral |
| |
|
Tegafur (INN) is a chemotherapeutic 5-FU prodrug used in the treatment of cancers. It is a component of tegafur-uracil. When metabolized, it becomes 5-FU.
See also
|
|||||||||||||||||||||||||||
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)




